Develop intermediates for the production of products whose patents will expire. As many of the top-selling patented drugs expire, their production will require most intermediates, such as o-tolybenzonitrile.
| Develops and produces pharmaceutical intermediates within the patent period
Patented drugs are very profitable, making their apis and intermediates highly profitable, and establishing good partnerships with these companies to produce intermediates for such drugs will have extremely high returns. Pharmaceutical intermediates companies are mostly large pharmaceutical companies within the patent period of product joint research and development production of intermediates, on the one hand, there is a fixed gross margin, very few competitors, on the other hand, joint research and development to reduce the cost of the production process.
Strengthen technological innovation and develop new drug intermediates;
The replacement of drugs is fast, and the technical content plays a decisive role in the production of pharmaceutical intermediates. Intermediate R & D and production enterprises should strengthen the technical reserves of various synthetic reactions and develop innovative technologies, improve the GMP system and intellectual property protection system, and develop products with relatively high technical level requirements and need a large number of imported products.
Bulk API intermediates with raw material gaps
Fluoroquinolones and other fluorine-containing drugs: fluorobenzenes have excess capacity, trifluorotoluene has developed rapidly, and there are few studies on fluorine-containing heterocycles and thick rings. Vitamin upstream intermediates :VA’s β-ionone and citronal, VE’s three base hydroquinone replacement imports, VB12, VD3, pantothenic acid, folic acid, niacin, VK, VH, Coenzyme Q10, carotenoids and lipoic acid, etc., rapid growth, great potential.
Intermediate of coryspora: nuclear 7-ACA, 7-ADCA, GCLE; Some side chains are tight, such as HO-EPCP, methoxyamine hydrochloride, furan amine salt, etc.
Customize chemicals to CDMO companies
For European and American pharmaceutical companies, it is a trend to shorten the production process route as much as possible and carry out large-scale transfer of intermediates for the production of apis. In this transfer process, the advantages of China and India are obvious, and the growth prospects of the custom chemicals market are very promising.
Pharmaceutical intermediates research and development and production enterprises should vigorously do a good job of environmental protection
National environmental inspection of chemical enterprises production pressure is greater, many projects due to environmental protection reasons, etc., enterprises gradually increase investment in environmental protection, and further squeeze the living space of small intermediate production enterprises, the industry will gradually to the leading, environmental protection investment, facilities of enterprises concentrated.
| Pharmaceutical intermediates R & D and production enterprises to strengthen the contact with domestic and foreign pharmaceutical enterprises
Pharmaceutical intermediates enterprises need to join forces with large pharmaceutical enterprises to establish a long-term and stable loan relationship, which is conducive to stable product sales, guaranteed capital return, and conducive to opening up domestic and foreign sales channels to avoid anti-dumping trade and technical barriers.
About Wisdom Drugs
Wisdom Drugs Co .,Ltd was founded in Sep. 2011 whose headquarter located in Changzhou Creative Industry Park, having a branch in India. The company’s R&D center is engaged in not only the process development of APIs, intermediates, poly-peptide compounds and heterocyclic compounds,but also the optimization and production. We are devoted to the synthesis customization and the technology transfer, enabling compounds to be scaled from laboratory to commercial to meet the requirements of different customers.
